EXPLORING BEE VENOM VOLATILES: A PROMISING AVENUE FOR CYSTIC FIBROSIS

Bee venom, a complex mixture of bioactive compounds, has demonstrated anti-inflammatory, antimicrobial, and immunomodulatory properties. Notably, the volatiles released by bee venom components have garnered attention for their potential in respiratory-related disease conditions. Cystic fibrosis (CF) is a challenging disorder, characterized by a genetic mutation affecting the CFTR protein, leading to the production of thick and sticky mucus in various organs, particularly the lungs and digestive system, and necessitating innovative therapeutic approaches. This research explored both bee venom volatiles’ chemical composition and the effects on airway inflammation and mucus viscosity in CF patients by in silico methods. GC/MS analyses with various SPME fibers have conducted the identification of 67 distinct components in volatile compounds of bee venom. For CW/DVB, CAR-PDMS, and DVB-PDMS fibers, the compounds identified in the highest amounts were perilla alcohol (42.21%), tetradecane (11.48%), and 1,2-benzenedicarboxylic acid, 1,2-bis(2-methylpropyl) ester (39.98%), respectively. In silico analyses subsequently indicated that these components exhibit anti-inflammatory effects by modulating key cytokines and reducing inflammatory markers in CF airways. This research highlights the potential of bee venom volatiles as a novel therapeutic avenue for managing CF symptoms. Harnessing the unique properties of bee venom may offer new perspectives in the development of targeted therapies for individuals affected by cystic fibrosis.